ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
January 02, 2025 20:00 ET | Source: ACELYRIN, INC. LOS ANGELES, Jan.…
U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2
Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor1 Given…
DARZALEX (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma
First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and…
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
− Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown…